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ABSTRACT 
Childhood nephrotic syndrome (NS), in which steroid-dependence occurs concurrently with 
steroid-resistance, requires aggressive therapy to prevent relapse. Predictive biomarkers that 
can be used to stratify treatment are urgently needed. Here we report that reciprocal 
regulation of the glucocorticoid metabolizing enzymes, 11β-hydroxysteroid dehydrogenase 
(11β-HSD) types 1 and 2 is associated with steroid-responsiveness and disease remission in 
childhood NS, potentially providing a marker to identify patients in which aggressive therapy 
is required. 
 
Synthetic glucocorticoids (GCs) are used as the first-line treatment for childhood idiopathic 
nephrotic syndrome (NS). The initial response to steroids is a major prognostic factor in 
childhood NS.
1
 More than 90% of children with minimal change nephrotic syndrome 
(MCNS) achieve initial remission after an 8-week course of prednisolone on the International 
Study of Kidney Disease in Children (ISKDC) protocol.
2
 However around 60% of steroid-
responsive patients experience frequent relapses with some becoming dependent on steroids 
to prevent further relapse, but requiring higher doses to do so (exhibiting relative resistance to 
steroids).
2
 The mechanisms underlying the development of steroid resistance remain unclear 
and there are currently no reliable biomarkers to identify patients who will go on to develop 
steroid dependence and resistance. A recent report suggests that low levels of glucocorticoid 
receptor (GR) in peripheral blood mononuclear cells (PBMCs) are associated with GC 
resistance in childhood NS.
3
 However, the density and binding affinity of GRs, as determined 
by dexamethasone binding assays in PBMCs, were not different in children with steroid 
sensitive and resistant NS.
4
 Thus, whether GR in PBMCs are a useful biomarker in NS is 
unclear. We have previously shown that both the type 1 and type 2 isozymes of the pre-
receptor GC metabolizing enzyme, 11β-hydroxysteroid dehydrogenase (11β-HSD1 and 11β-
HSD2, respectively) are associated with steroid sensitivity in childhood acute lymphoblastic 
leukemia and indeed, that 11β-HSD2 may contribute to steroid resistance.
5,6
 Therefore, we 
hypothesized that 11β-HSDs in PBMCs could be associated with steroid responsiveness in 
childhood NS. 
CASES AND METHODS 
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We studied all the Japanese nephrotic syndrome children who were treated at Seirei 
Hamamatsu General Hospital between April 2013 and October 2015 (a total of 8). Peripheral 
blood samples were obtained with informed consent. Study protocols were approved by the 
ethics committee of our hospital. Diagnosis of idiopathic nephrotic syndrome was made by 
pediatric nephrologists based on clinical and laboratory findings. Patient profiles are shown 
in Table 1. We had four newly diagnosed and four relapsed NS. Prednisolone treatment was 
initiated in all patients. For newly diagnosed patients (patients 1, 3, 4 and 8) (Table 1), 
induction therapy used 2 mg/kg/day prednisolone for 4 weeks (60 mg/m
2
/day) according to 
the ISKDC protocol. Because we hypothesized that there would be a qualitative difference 
between early and late responders, we determined clinical GC-sensitivity/resistance from the 
initial response to prednisolone treatment at 2 weeks. This is earlier than the common 
definition (at 4 weeks), but in concordance with a recent report suggesting that the initial 
response to steroids (at 7 days) is a major prognostic factor in idiopathic NS.
1
 Therefore 
patients 1, 3 and 4, who showed complete resolution of proteinuria (urine protein/creatinine 
ratio less than 0.2) at 2 weeks and remained negative until 4 weeks, were classified as GC-
sensitive. Patient 8 was classified as GC-resistant as she failed to respond to the initial 
prednisolone treatment. Her histological finding revealed focal segmental glomerulosclerosis 
on renal biopsy (Table 1). 
Of the four relapsing nephrotic syndrome patients, one was classified as infrequent relapse 
(patient 7). The remaining three (patients 2, 5 and 6) were frequent relapsing nephrotic 
syndrome patients (FRNS). Modified induction therapy was initiated according to our 
regional protocol (Nagoya City Kidney Disease Study Group).
7
 According to this protocol, if 
FRNS patients are not prescribed prednisolone before relapse, to reduce steroid toxicity, 1 
mg/kg dose of prednisolone (maximum dose of 30 mg/m
2
/day) is administered initially, 
which is lower than the common protocol. Patients already undergoing treatment with ≥1 
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mg/kg prednisolone are started on 2 mg/kg prednisolone daily. For infrequent relapse patient 
7, 2 mg/kg prednisolone was administered daily (60 mg/m
2
/day) until the proteinuria 
disappeared. We classified patient 7 as GC-resistant due to the presence of proteinuria at 2 
weeks, although this had disappeared at 4 weeks. FRNS patients 2, 5 and 6 were all treated 
with 1 mg/kg prednisolone therapy at relapse. 
Blood sampling was carried out before prednisolone treatment and at 2 weeks and 4 weeks 
after initiating prednisolone treatment. PBMC were isolated by density gradient 
centrifugation (Ficoll-Paque; Pharmacia). Cells were cultured for 24h in the presence or 
absence of 10
-6 
M dexamethasone in RPMI-1640 with 10% fetal calf serum, penicillin (100 
U/mL) and streptomycin (100 µg/mL) (all Invitrogen), at 37 ◦C, 5% CO2. RNA was extracted 
following homogenisation in Trizol (Invitrogen) and resuspended in RNase-free water. RNA 
(1 µg) was reverse transcribed using SuperScript III (Invitrogen) and quantified by real-time 
PCR on a LightCycler (Roche) as previously described.
5,6
 All experimental procedures were 
carried out at Hamamatsu University School of Medicine. Mastermix and primer-probe sets 
for HSD11B1, HSD11B2, NR3C1 (encoding GR) and 18S RNA were purchased from 
Applied Biosystems. 18S RNA served as the internal control. The fold induction of 
HSD11B1, HSD11B2 and NR3C1 mRNA levels were calculated, relative to levels in vehicle 
treated cells. Values are mean±SEM. Date were analysed in each group using the Wilcoxon 
matched pairs test. Significance was set at p < 0.05.  
RESULTS AND DISCUSSION 
HSD11B1, HSD11B2 and NR3C1 mRNA were expressed in PBMC in all cases. Absolute 
levels varied between patients, so findings are expressed as fold induction following 
dexamethasone. HSD11B1 mRNA levels were decreased following in vitro dexamethasone 
treatment of PBMC collected from all patients, before or following prednisolone treatment 
(Fig 1A).  The decrease in HSD11B1 mRNA levels following dexamethasone tended to be 
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lower in GC-resistant than in GC-sensitive NS, although this did not achieve significance 
(Fig 1A). In contrast, HSD11B2 mRNA levels were unchanged by dexamethasone treatment 
of PBMC collected from GC-sensitive NS patients either prior to or following their 
prednisolone treatment (the fold induction was not significantly different to 1) (Fig 1B). 
However, HSD11B2 mRNA levels were significantly increased by dexamethasone treatment 
of PBMC collected from GC-resistant NS patients both prior to, and following, their 
prednisolone therapy at 2 weeks (Fig 1B). The different responses of HSD11B1 and 
HSD11B2 mRNAs following in vitro dexamethasone revealed a qualitative difference 
between GC-sensitive and resistant NS, as seen in GC-sensitive and resistant childhood 
lymphoblastic leukemia.
5
 Th  patterns of HSD11B1 and 2 remained similar during the course 
of prednisolone therapy, suggesting that GC-sensitivity/resistance is intrinsic in childhood NS. 
Levels of NR3C1 mRNA, encoding GR, were unaffected by in vitro treatment of PBMC with 
dexamethasone (Fig 1C). 
Expression of 11β-HSD1 and 11β-HSD2 is normally reciprocally regulated.
8
 In vivo, 11β-
HSD1 predominantly activates endogenous glucocorticoids (converting cortisone to cortisol) 
whereas 11β-HSD2 catalyses the reverse reaction, inactivating glucocorticoids. However, it 
should be noted that 11β-HSD2 is a high affinity though low capacity enzyme and thus high 
levels of glucocorticoids can escape inactivation.
8
 The 11β-HSD enzymes potently modulate 
exogenous GC action as well. They interconvert prednisolone (active) and prednisone (inert), 
which itself does not bind to GR.
8 
In many tissues, there is a switch from 11β-HSD2 to 11β-
HSD1 expression as cells differentiate and mature.
9,10
 The precise mechanism of this 
reciprocal regulation remains largely unknown, but transcriptional regulator CAAT/enhancer-
binding proteins (C/EBPs) are likely involved, as we have previously shown that they 
regulate 11β-HSDs in a variety of cell types.
11,12
  
In normal PBMCs, 11β-HSD1 expression is low and 11β-HSD2, negligible.
8
 However in 
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certain disease conditions, such as early rheumatioid arthritis, levels of mRNA encoding 11β-
HSD2 in PBMC are increased; indeed, 11β-HSD2 has been reported as a PBMC marker of 
early rheumatoid arthritis.
13
 Similarly, 11β-HSD2 is expressed in glucocorticoid-resistant 
leukemic cell lines where it contributes to prednisolone resistance.
6
 Up-regulation of 
HSD11B2 coupled with down-regulation of HSD11B1 may reflect a return to an earlier 
developmental state in GC resistant NS. Alternatively, the qualitative difference in 11β-HSD 
expression between steroid sensitive and resistant NS may reflect a stable state. This may 
arise, for example from epigenetic mechanisms
14
 which, once established, become self-
perpetuating. In steroid-resistant NS, induction of 11β-HSD2 is predicted to inactivate and 
thus attenuate prednisolone action, whereas the opposite is predicted for 11β-HSD1. Thus, in 
steroid-resistant NS, higher doses of prednisolone are needed to overcome the 11β-HSD2 
inactivation. Therefore we suggest that dexamethasone should be used to treat this condition, 
rather than prednisolone. The present study has some limitations. We evaluated only Japanese 
NS patients at our hospital, who may not be representative of childhood idiopathic NS 
patients in other ethnic groups. Frequent relapse patients were treated with a lower dose of 
prednisolone (1 mg/kg/day), according to our regional protocol which is intended to reduce 
steroid toxicity.
7
 Moreover, the sample size is small, and statistical significance was not 
achieved for the HSD11B1 mRNA findings. Therefore our findings are preliminary, 
qualitative rather than quantitative, and require confirmation in a larger number of patients. 
Nevertheless, they suggest that analysis of expression of these isozymes, and their regulation 
by glucocorticoids in nephrotic syndrome may aid in tailoring steroid treatment to the patient, 
by serving as prognostic biomarkers of disease activity. 
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FIGURE LEGENDS 
FIGURE 1. Fold induction of 11β-HSD1/2 and GR mRNA levels in PBMCs in childhood 
nephrotic syndrome patients during prednisolone treatment. 
11β-HSD1 (A), 11β-HSD2 (B) and GR mRNA (C) levels relative to before in vitro 
dexamethasone. Open bars indicate GC-sensitive NS and black bars indicate GC-resistant NS. 
Data are mean±SEM. *indicates significant effect of treatment, p < 0.05. 
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Table 1. Patient Profiles
Age at diagnosis Disease status Pathophysiology Urine protein/creatinine ratio (g/gCr)
patient year/sex at sampling before 2 weeks 4 weeks
Glucocorticoid 1 4/M diagnosis n.d. 10.73 0.1 0.08
sensitive 2 11/M relapse MCNS 6.72 0.04 0.07
3 2/F diagnosis n.d. 13.35 0.05 0.09
4 6/M diagnosis n.d. 3.65 0.03 0.02
Glucocorticoid 5 4/M relapse MCNS 2.39 0.07 1.99
resistant 6 13/M relapse MCNS 1.94 1 0.03
7 10/M relapse FSGS 17.68 2.89 0.18
8 3/F diagnosis FSGS 6.18 2.03 1.64
Abbreviations: n.d., not determined; MCNS, minimal change nephrotic syndrome; FSGS, focal segmental glomerulosclerosis
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Cases and Methods section. 
Page 4, lines 19 
– Page 5, 
lines 5 
 
3. Used statistical methods and tests 
should be mentioned. 
The data were analysed using the Wilcoxon matched pairs test. This has been 
added to the Cases and Methods section as well as the Figure Legend. 
Page 5, lines 18 
- 19 
 
4. In Figure 1; HSD11B1, HSD11B2 and 
NR3C1 expression levels should be 
illustrated and P values should be 
written either on the figure if 
applicable or in the results section. 
We did consider this when presenting our data. However, the absolute levels of 
HSD11B1, HSD11B2 and NR3C1 mRNA were measured on different days, so 
variance between patients may reflect differences in assay conditions. However, 
samples from the same patient were always assayed together, so we have 
presented the results as the fold induction following dexamethasone treatment. 
This is now mentioned in the Results and Discussion section. P values have been 
added to the figure. 
Page 5, lines 16 
- 23 
 
Reviewer 2’s comment 
1. The authors did not identify 
inclusion and exclusion criteria for 
their subjects. Thus it is unclear if 
these are children with idiopathic 
nephrotic syndrome in whom they 
are studying. Further they did not 
specify the case definition by which 
they diagnosed these patients with 
All childhood NS patients admitted in our hospital for the duration of this study 
were included, with informed consent. The diagnosis of idiopathic nephrotic 
syndrome was made by pediatric nephrologists based on clinical and laboratory 
findings and this information is now included in the Cases and Methods section.  
Page 4, lines 1 - 
5 
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nephrotic syndrome. 
2. Regarding the subjects that they 
studied, they did not specify the 
ethnicity of their subjects. 
Presumably these patients are 
Japanese, but it is not specified. 
This is important because the 
underlying presumption is that the 
differences in steroid 
responsiveness is dictated by gene 
expression levels of HSD11B1 and 
HSD11B2. If this is the case, then 
there is a presumption that there is 
some type of gene variant 
responsible for the differences in 
gene expression, epigenetics, or 
gene-environment interaction. 
Thus, the underlying gene variants 
may or may not be present in other 
populations (which is important in 
considering the generalizability of 
the observation to other 
populations). 
Reviewer 2 is correct, all the patients were Japanese. This information has been 
added to the Cases and Methods section. We also added a comment on this as a 
study limitation in the Results and Discussion section, as suggested by the 
Reviewer. 
Page 4, lines 1-2  
Page 7, lines 13-
15 
 
3. The medication dosing and clinical 
response of each case was not 
described so as to verify the degree 
of steroid resistance of the non-
responders. 
Both Reviewers raised this important point. We apologise that this was unclear. 
For newly diagnosed patients, induction therapy was initiated with 2 mg/kg 
prednisolone for 4 weeks (60 mg/m
2
/day), according to the ISKDC protocol. 
Relapse patients were treated according to our regional protocol which states 
that if patients are not prescribed prednisolone before relapse, then to reduce 
steroid toxicity, initially 1 mg/kg prednisolone (maximum dose of 30 mg/m
2
/day) 
is administered, which is lower than the common protocol. Patients already 
undergoing treatment with ≥1 mg/kg prednisolone are started on 2 mg/kg 
prednisolone daily. For the infrequent relapse patient (patient 7), daily 
Page 4, lines 6 – 
Page 5, lines 
5 
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prednisolone was administered at a dose of 2 mg/kg (60 mg/m
2
/day) until the 
proteinuria disappeared. The 3 frequently relapsing nephrotic syndrome patients 
were all treated with 1 mg/kg prednisolone therapy at relapse. We determined 
clinical GC-sensitivity/resistance by the initial response to prednisolone 
treatment at 2 weeks, which is earlier than the 4 weeks commonly used as we 
hypothesized that there is a qualitative difference between early and late 
responders, and because a recent report has shown the early response (at 7 
days) is of prognostic in nephrotic syndrome patients. This information is now 
included in the Cases and Methods section. 
4. In the results, the describe the 
testing of the mRNA levels for the 
above genes but do not report the 
statistics of their results, which one 
is to presume that they did not 
detect statistically significant 
difference in mRNA expression 
profiles between steroid responders 
and non-responders. 
Data were analysed using the Wilcoxon matched pairs test. This is now 
mentioned in the Cases and Methods section and also the Figure legend. 
HSD11B2 mRNA levels were significantly increased by dexamethasone treatment 
of PBMC collected from GC-resistant NS patients both prior to, and following, 
their prednisolone therapy at 2 weeks. The text of Results and Discussion has 
been amended to clarify this point. 
Page 5, lines 16 
– Page 6, 
lines 7 
 
5. The write up of the conclusions 
could be stronger. For example they 
could have tried to discuss the 
significance of their findings in the 
context of the literature they made 
reference to in their introduction. 
Furthermore, a discussion of the 
strengths and weaknesses of the 
study would have also been 
appropriate. 
We thank the Reviewer for these helpful suggestions. We have incorporated 
both comments on the significance of our study and discussed its limitations in 
the revised manuscript. 
Page 6, lines 25 
– Page 7, 
lines 22 
 
 
 
Instructions: 
Please use this table format to answer the questions posed by the editors and reviewers of your paper. Copy and paste the editor/reviewer’s question in the  
“Comments” column and your answer to that question in the corresponding “Response” column. Be sure to ALSO paste the corrected text along with your response. 
For minor copyediting changes such as spelling and grammar corrections, you may simply state that the error was corrected, without pasting the altered text. 
Page 14 of 15
The American Academy of Pediatrics, 141 Northwest Point Blvd., Elk Grove Village, IL 60007
Confidential - Not for Circulation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Review Copy
 5
 
For clarity, use one row per question. Make sure to list the page and line reference where your change can be found. If no change was made, please make sure to note 
that in your response in addition to your reasoning. You may delete the sample row and insert rows to this table as needed.   
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